MaxGlaViT: A novel lightweight vision transformer-based approach for early diagnosis of glaucoma stages from fundus images

TL;DR

MaxGlaViT is a lightweight, transformer-based model that significantly improves early glaucoma detection accuracy from fundus images through architectural enhancements and extensive validation.

Contribution

The paper introduces MaxGlaViT, a novel lightweight vision transformer architecture optimized for early glaucoma diagnosis, outperforming existing models on the HDV1 dataset.

Findings

MaxGlaViT achieved 92.03% accuracy in glaucoma stage classification.

Adding ECA and ConvNeXtV2 blocks improved model performance.

MaxGlaViT outperformed state-of-the-art CNN and ViT models.

Abstract

Glaucoma is a prevalent eye disease that progresses silently without symptoms. If not detected and treated early, it can cause permanent vision loss. Computer-assisted diagnosis systems play a crucial role in timely and efficient identification. This study introduces MaxGlaViT, a lightweight model based on the restructured Multi-Axis Vision Transformer (MaxViT) for early glaucoma detection. First, MaxViT was scaled to optimize block and channel numbers, resulting in a lighter architecture. Second, the stem was enhanced by adding attention mechanisms (CBAM, ECA, SE) after convolution layers to improve feature learning. Third, MBConv structures in MaxViT blocks were replaced by advanced DL blocks (ConvNeXt, ConvNeXtV2, InceptionNeXt). The model was evaluated using the HDV1 dataset, containing fundus images of different glaucoma stages. Additionally, 40 CNN and 40 ViT models were tested on HDV1 to validate MaxGlaViT's efficiency. Among CNN models, EfficientB6 achieved the highest accuracy (84.91%), while among ViT models, MaxViT-Tiny performed best (86.42%). The scaled MaxViT reached 87.93% accuracy. Adding ECA to the stem block increased accuracy to 89.01%. Replacing MBConv with ConvNeXtV2 further improved it to 89.87%. Finally, integrating ECA in the stem and ConvNeXtV2 in MaxViT blocks resulted in 92.03% accuracy. Testing 80 DL models for glaucoma stage classification, this study presents a comprehensive and comparative analysis. MaxGlaViT outperforms experimental and state-of-the-art models, achieving 92.03% accuracy, 92.33% precision, 92.03% recall, 92.13% f1-score, and 87.12% Cohen's kappa score.